Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Novan
Durham, North Carolina, United Statesnovan.com ↗
- Ownership
- Public · NOVN
- Employees
- ~50
- Development stage
- Other
01
Overview
Berdazimer gel was the lead asset; it reached NDA submission with a PDUFA date in early 2024 as a potential first at-home treatment for molluscum contagiosum. The broader pipeline included late-stage programs in acne and external genital warts but faced financial challenges leading to bankruptcy and asset sale to Ligand Pharmaceuticals[1][7].
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Small moleculeNitric oxide-based drugs
- Industry
- Biotech
02
Partnerships
Collaborations with academic institutions such as University of North Carolina, Pennsylvania State University, University of Alabama-BirminghamBayer-partnered Sitavig program transferred to Ligand upon acquisition
Beyond the preview
Go deeper on Novan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novan.